Avastin’s Off-Label Uptake May Be Slowed By ASP-Based Reimbursement
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare reimbursement changes make oncologists more likely to adhere to established treatment guidelines, Robert W. Baird analyst says.
You may also be interested in...
Genentech Aims To Extend Avastin Duration Of Use
Physicians have been treating first-line colorectal cancer patients for less time than the product was used for in clinical trials, Exec VP Clark says.
Genentech Aims To Extend Avastin Duration Of Use
Physicians have been treating first-line colorectal cancer patients for less time than the product was used for in clinical trials, Exec VP Clark says.
CMS Extends Oncology Quality Of Care Demo
The 2006 version of the demo project is expected to require that oncologists report clinical guideline adherence, rather than assess symptoms related to patient suffering.